Transfection of the costimulatory molecule B7-1 (CD80) into murine tumors can increase antitumor immunity and eradicate tumor growth. The purpose of this study was to test autologous lymphocyte responses against freshly resected human cancers infected in vitro with an adenovirus vector expressing the B7-1 molecule (AdB7). Resected tumors (sarcomas, adenocarcinomas, melanomas, and multiple myelomas) were disaggregated into single-cell suspensions and divided into three groups: (a) native, noninfected tumor cells (TM); (b) AdB7-infected, B7-1 ϩ tumor cells (TMB7); and (c) control Addl70.3-infected, B7-1 Ϫ tumor cells (TMAd). B7-1 expression was verified by flow cytometry. Autologous peripheral blood lymphocytes from these patients were tested for proliferative and cytotoxic activity against the three tumor groups. There was an increased lymphocyte-proliferative response against B7-1 ϩ tumor cells, particularly in the presence of interleukin-12 (IL-12) or low-dose IL-2. B7-1 ϩ tumor cells were also killed more efficiently than B7-1 Ϫ tumor cells in natural killer cell-mediated cytotoxicity assays, and this was most significant when lymphocytes had been pretreated with IL-12. Human natural killer cells were found to express CD28, a receptor for B7-1. The high efficiency of AdB7-mediated gene transfer and the augmented B7-1-mediated lymphocyte responses suggest that AdB7 vectors may be effective in human cancer immunotherapy.
R ecent studies using animal models have demonstrated an important role for B7-1, a costimulatory molecule, in the induction of antitumor immunity in vivo.
1-10 B7-1 is normally expressed on activated B cells and other professional antigen (Ag)-presenting cells (APCs). [11] [12] [13] [14] [15] Without costimulation, recognition of Ag by T cells may result in unresponsiveness, anergy, or programmed cell death. 12, 16 Delivery of both an Agspecific signal, via the T-cell receptor in the context of the major histocompatibility complex (MHC), and a costimulatory signal, resulting from the interaction of T-cell CD28 receptors with B7-1 ligand, is essential for optimal T-cell stimulation. 17, 18 This results in the increased production of several lymphokines, including interleukin-2 (IL-2) and interferon-␥, 19 -21 leading to the proliferation of CD4 ϩ T cells and cytolytic activity of CD8 ϩ T cells. 18, 22, 23 The transfection of B7-1 into murine tumor cell lines increases antitumor T-cell immunity and leads to tumor regression in many models. [1] [2] [3] [4] [5] [6] [7] Murine cell lines that remain tumorigenic after B7-1 gene transfer fail to present an adequate Ag-specific first signal (low T-cell receptor ligand density/affinity) 6 -9,24 or fail to present other necessary adhesion molecules, such as intercellular adhesion molecule-1. 25 Other recent reports indicate that natural killer (NK) cell activity may also be affected by costimulatory molecules. Depletion experiments involving the administration of monoclonal antibodies (mAbs) in vivo indicated that NK cells are involved in the rejection of B7-1-transfected tumor cells in some murine models. 24 -26 In vitro cytotoxicity studies also support an enhanced activation of NK cells by B7-1. 26 -28 Geldhof et al showed that B7-1 expression leads to the NK cell-mediated elimination of metastasizing, NK-resistant mouse T lymphoma cells. 27 Yeh et al reported that B7-1 enhances NK cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine lung carcinoma. 26 Chambers et al demonstrated that B7-1 functions as a triggering signal for murine NK cell-mediated cytotoxicity, and that the strength of this response overrides the negative signal mediated by MHC class I molecules. 28 Azuma et al described B7-1/CD28-mediated cytotoxic activity by YT2C2, a human NK leukemia cell line. 29 It is well established that murine NK cells express CD28, 30 and that the human NK leukemia cell line YT2C2 also expresses CD28, 29 but it has been reported that adult human NK cells are normally CD28 Ϫ . 31 We show here that approximately one-third of normal adult human CD56 ϩ /CD16 ϩ NK cells express CD28.
Experimental animal models are valuable in the study of tumor immunology and in vivo immune mechanisms, but there are limitations in the extrapolation of murine studies to human cancer immunotherapy. First, human APCs process antigenic peptides in the context of human MHC for human T-cell recognition. MHC-binding motifs are species-specific, and antigenic epitopes that contribute to tumor immunogenicity in the mouse may not be significant in humans. Specific immune responses and clinically significant antitumor effects cannot be predicted from animal models alone. Second, most animal models use established cell lines in which tumor Ags are selected over time. Culture conditions may result in the selection of Ags that are not normally present in vivo. Mouse tumor models are inbred, and consequently fail to reflect the heterogeneity seen in human tumors. Humans develop tumors that express a heterogeneous panel of (presumably) weak immunogenic tumor Ags. Human cancer cell lines acquire a selected phenotype in culture, and so freshly resected spontaneous tumors best represent tumors found in the clinical situation. Finally, many animal models have used stably transfected B7-1 ϩ tumor cells generated using retroviral vector systems, lipofection, or electroporation. These methods of transduction are inefficient and usually require drug selection of transduced cells in culture. Fresh human cancer specimens are not easily amenable to such means of gene transfer, and require a system that DESSUREAULT, GRAHAM, GALLINGER: LYMPHOCYTE RESPONSES TO B7-1 ϩ HUMAN CANCER CELLS is highly efficient, rapid, and does not require host cell proliferation. Hodge et al have constructed a recombinant vaccinia virus containing the murine B7-1 gene and have shown that infection of tumor cells with this vector leads to rapid and efficient cell surface expression of B7-1. 3 We have recently described the construction of an adenovirus-B7-1 (AdB7) expression vector containing human cDNA, and we have shown that it is a rapid and highly efficient means of gene transfer into freshly resected human tumor cells. 32 In the experiments to be described, our goal was to study the immunologic effects of B7-1 gene transfer into human cancer cells in vitro. We have shown previously that B7-1 mediates increased allogeneic T-cell-proliferative responses against WM35 melanoma tumor cells that express MHC molecules (class I ϩ II ϩ ) and antigenic epitopes, but not against MeWo and H125 cells, which presumably fail to deliver an adequate Ag-specific signal that can be costimulated by B7-1/CD28 interaction. 33 We also showed that human NK cell-mediated cytotoxic responses could be enhanced in a stable cell line system. 33 In the present study, we sought to test the hypothesis that B7-1 expression by human tumor cells could enhance autologous T-cell and NK cell responses in vitro. We used freshly resected cancer specimens to reflect the heterogeneous nature of spontaneous tumors found in the clinical situation. These tumor cells were efficiently transduced with the AdB7 expression vector. 32 Peripheral blood lymphocytes (PBLs) from cancer patients were tested in vitro for both proliferative and cytotoxic activity against three groups of autologous tumor cells: (a) native, noninfected tumor cells (TM); (b) AdB7-infected, B7-1 ϩ tumor cells (TMB7); and (c) Addl70.3-infected, B7-1 Ϫ tumor cells (TMAd). We cor- We also studied the effect of IL-2 and IL-12 on these autologous B7-1-mediated lymphocyte responses. IL-12, a 75-kDa heterodimeric glycoprotein, was first recognized by its ability to augment cytotoxic T lymphocyte (CTL) responses 34, 35 and NK cell activity; 36 it was initially isolated from B-lymphoblastoid cell lines and called NK cell stimulatory factor 36 and cytotoxic lymphocyte maturation factor. 37 IL-12 synergizes with IL-2 in several activities, including interferon-␥ production, 38, 39 enhancement of NK cytolytic activity, 36, 40 and proliferation of activated T and NK cells. 41, 42 Kubin et al have shown that IL-12 also synergizes with B7-1/CD28 interaction in inducing efficient proliferation and cytokine production in human T cells. 43 IL-12 has been shown to promote T helper type 1-specific immune responses 44 -46 and induce potent antitumor activity in animal models, 47 acting synergistically with both IL-2 48 -50 and B7-1.
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MATERIALS AND METHODS
Patients
Blood and tissue specimens were obtained from patients at Mount Sinai Hospital and Toronto Hospital (Toronto, Ontario, Canada). Ethics committee approval (University of Toronto) was obtained, and patients gave informed consent before donating blood for the study.
PBLs
Peripheral blood was obtained from patients in heparinized vacutainers. Lymphocytes were separated by Ficoll-Hypaque gradient centrifugation, washed twice with phosphate-buffered saline (PBS), counted, and resuspended in culture medium as described below.
Adenoviral expression vectors
The AdB7 vector has been described previously. 32 Briefly, the B7-1 cDNA (800 base pairs) resides in the E1 region of an E1/E3-deleted Ad5 virus. A negative control virus, Addl70.3, is an adenovirus vector with the same E1/E3 deletion, but no B7-1 sequence. Techniques for virus growth and purification are described elsewhere. 53, 54 Viral titers were determined by plaque-forming unit assays on 293 cell monolayers.
Human tumor cells
Bone marrow specimens of patients with multiple myeloma were obtained during routine marrow aspirates. Red blood cells were lysed with ammonium chloride. Cells were then washed and resuspended in RPMI 1640 medium (Life Technologies, Grand Island, NY) at a concentration of 2-4 ϫ 10 6 cells/mL for viral adsorption (described below).
Freshly resected solid tumors were disaggregated into single-cell suspensions by aseptic mechanical dissociation into 1-4-mm fragments (within 30 minutes of surgical resection), followed by digestion with a collagenase-based enzymatic cocktail: 2 mg/mL collagenase, 0.3 mg/mL deoxyribonuclease I, and either 0.2 mg/mL pronase E (protease type XXV) or 0.3 mg/mL hyaluronidase type V (all from Sigma, St. Louis, Mo) in RPMI 1640 medium. The tissue fragments were exposed to the enzyme cocktail and stirred vigorously with a sterile magnetic bar for 2-4 hours at room temperature (until most fragments were fully digested). Single cells were obtained by filtration of the mixture through a sterile 44-m nylon filter (Small Parts, Miami Lakes, Fla) and centrifugation of the supernatant. Cells were washed and resuspended in RPMI 1640 medium at a concentration of 2-4 ϫ 10 6 cells/mL. Each tumor cell suspension was divided into three groups: (a) native, mock-infected tumor cells (TM); (b) AdB7-infected, B7-1 ϩ tumor cells (TMB7); and (c) Addl70.3-infected, B7-1 Ϫ tumor cells (TMAd). Cells were infected with AdB7 or Addl70.3 (negative control) at a multiplicity of infection of 10 -20. Control cells were mock-infected with PBS. Viral adsorption was performed at 37°C for 60 minutes. Cells were then washed with RPMI 1640 medium and resuspended in appropriate media (AIM-V (Life Technologies) for proliferation assays; RPMI 1640 medium plus fetal bovine sera (FBS) (Life Technologies) for culture). Cells were maintained in culture at 37°C in RPMI 1640 medium supplemented with 20% FBS (except for breast adenocarcinoma tumor cell cultures, for which only 5% FBS was added to prevent fibroblast overgrowth). 55 Cell culture viability was maintained best when using Falcon polystyrene tissue culture flasks (Becton Dickinson Labware, Franklin Lakes, NJ).
Immunostaining and flow cytometric analysis
Harvesting tumor cells. Tumor cells were harvested for immunostaining after variable times in culture (24 hours to 6 weeks). Cells were gently scraped off the tissue culture flask, washed, counted, and resuspended in RPMI 1640 medium plus 10% FBS. Cells not used for immunostaining were either used in cytotoxicity assays or returned to culture for later use. The immunostaining of multiple myeloma samples is described elsewhere.
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B7-1 expression. Tumor cells were first incubated for 45 minutes at 4°C with either BB1 (a murine immunoglobulin G1 (mIgG1) mAb that recognizes human B7-1) or a mIgG1 isotype control antibody (Ab) (Becton Dickinson, San Jose, Calif) at 5 g/mL in RPMI 1640 medium containing 10% FBS. Cells were then washed twice with PBS containing 1% FBS and incubated for an additional 45 minutes at 4°C with fluorescein isothiocyanate (FITC)-conjugated goat F(abЈ) 2 anti-mouse IgG (Caltag Laboratories, San Francisco, Calif). Cells were again washed twice with PBS plus 1% FBS and subsequently incubated with 0.125 g/mL ethidium monoazide (EMA) (Molecular Probes, Eugene, Oreg) on ice for 10 minutes under a fluorescent light source to photoactivate the EMA and covalently link it to the DNA of nonviable cells. 32 Next, cells were washed twice with PBS plus 1% FBS and fixed with 1% paraformaldehyde (BDH Inc., Toronto, ON). Stained cells were analyzed on an Epics Elite flow cytometer (Coulter Electronics, Miami, Fla). Cells were gated for live tumor cells using light scatter and EMA fluorescence. Raji cells (American Type Culture Collection (ATCC), Manassas, Va), which are derived from an Epstein-Barr virus-negative human Burkitt's lymphoma that expresses high levels of surface B7-1, were used as positive controls.
MHC class I expression. Cells were first incubated for 45 minutes at 4°C with either a rat mAb to human histocompatibility leukocyte class I Ag (Serotec, Oxford, U.K.) or a rat IgG2a isotype control Ab (Immunotech, Marseille, France) at 10 g/mL in RPMI 1640 medium containing 10% FBS. Cells were subsequently washed twice with PBS containing 1% FBS and incubated for an additional 45 minutes at 4°C with FITC-conjugated goat anti-rat IgG (Cedarlane Laboratories, Hornby, Ontario, Canada). Cells were again washed twice with PBS plus 1% FBS, incubated with EMA, fixed with 1% paraformaldehyde, and analyzed by flow cytometry as described above.
CD28 expression on normal human adult PBLs. PBLs from normal healthy adult human donors were cultured in the presence or absence of cytokines (IL-2 or IL-12 at 100 U/mL) for 18 hours in AIM-V medium at 5 ϫ 10 6 cells/mL. Cells were then harvested and incubated for 45 minutes at 4°C with either an FITC-conjugated rat anti-human CD28 Ab (Serotec) or an FITC-conjugated rat IgG2b isotype control Ab (Cedarlane Laboratories) at 2.5 g/mL in RPMI 1640 medium containing 10% FBS. The PBLs were simultaneously labeled with phycoerythrin (PE)-conjugated mouse anti-human CD56 Ab, PE-conjugated mouse anti-human CD16 Ab, or a PE-conjugated mIgG1 isotype control Ab (Becton Dickinson). Cells were subsequently washed twice with PBS plus 1% FBS and fixed with 1% paraformaldehyde. Stained cells were analyzed on an Epics Elite flow cytometer. Dead cells were excluded for analysis using forward light scatter. The percentage of CD28 ϩ cells within both the CD56 ϩ and CD16 ϩ populations of PBLs (NK cells) was determined by subtraction analysis.
[ 3 H]thymidine uptake T-cell proliferation assays
Patient PBLs were resuspended in sera-free AIM-V culture medium and plated into 96-well flat-bottom microtiter plates (Becton Dickinson Labware) at 10 5 cells/well. TM, TMB7, and TMAd tumor cells were plated at either 5000 or 100,000 cells/well in a final volume of 200 L. Negative controls included PBLs with medium alone and each of the tumor cell groups with medium alone. Positive controls included PBLs cultured with phytohemagglutinin (PHA) (Difco, Detroit, Mich). Some groups were cultured with exogenous IL-2 (Sigma); on day 3 of culture, some groups were treated with exogenous IL-12 (Sigma). When sufficient cells were available, extra groups were treated with 5 g/mL BB1 (a murine mAb that blocks B7-1) or with an azide-free mIgG1 (an irrelevant isotype-matched control Ab from PharMingen, San Diego, Calif) to block the proliferative responses mediated by B7-1. All groups were plated in triplicate. The cells were incubated for 6 days at 37°C and then pulsed with 1 Ci of [ Cr release NK cell-mediated cytotoxicity assays
Patient PBLs were used as effector cells in standard 4-hour 51 Cr release cytotoxicity assays. For some experiments, PBLs were maintained in culture (AIM-V) for 1-5 days before the cytotoxicity assay. Cells were separated into three groups and plated in flat-bottom, 24-well tissue culture plates (Corning Glass Works, Corning, NY) at 5 ϫ 10 6 cells/mL. PBLs in the first group were maintained in the absence of exogenous cytokines. PBLs in the second and third groups were maintained in the presence of IL-2 and IL-12, respectively (both at 100 U/mL). These effector cells (IL-2 lymphokine-activated killer (LAK) cells, IL-12 LAK cells, and NK cells incubated in the absence of cytokines) were then tested against autologous TM, TMB7, and TMAd 51 Cr-labeled target cells (5000 target cells/well; serial effector to target (E:T) ratios of ϳ50:1, 25:1, 12.5:1, 6.125:1, and Յ100:1 depending upon cell availability). Target cells were labeled by incubating 1 ϫ 10 6 cells in 200 L of RPMI 1640 medium plus 10% FBS with 100 Ci of 51 Cr-sodium chromate (DuPont) for 2 hours. The target cells were subsequently washed three times with PBS, resuspended in 20 mL of culture medium, and added in triplicate to the effector cells in 96-well V-bottom microtiter plates (Nunc, Roskilde, Denmark). The plates were spun at 500 revolutions per minute for 7 minutes and subsequently incubated for 4 hours at 37°C. Plates were then centrifuged again, after which 100-L aliquots of supernatant were harvested for the measurement of radioactivity in an automated ␥-counter (LKBWallac CliniGamma 1272, Wallac Oy, Turku, Finland). The spontaneous cpm released by target cells in the absence of PBLs and the maximal cpm released by target cells in the presence of 1% Triton X-100 were also determined. NKsensitive K562 target cells (ATCC) were used as positive controls. The percentage of specific lysis was calculated as follows: % specific lysis ϭ ([experimental cpm Ϫ spontaneous cpm]/[maximal cpm Ϫ spontaneous cpm]) ϫ 100%.
The number of effector cells required for 30% specific lysis (1 lytic unit (LU)) was calculated by linear regression analysis.
The number of LU per 10 6 effector cells was calculated for each group.
Statistics
The means of the percentage of B7-1 expression after AdB7 infection were compared by paired Student's t tests. The effect of tumor pathology on successful B7-1 gene transfer (arbitrarily defined as cell populations with Ͼ20% B7-1 ϩ cells after AdB7 infection) was tested using the 2 test. T-cell-proliferative responses (PI) and NK cell cytotoxic responses (LU per 10 6 effector cells) against the three tumor groups were compared by analysis of variance (SAS software). Various response transformations were used when necessary to improve the fit and satisfy model assumptions. 57 Lymphocyte responses to the three groups of tumor cells were correlated with the degree of tumor B7-1 expression, tumor MHC class I expression, and tumor pathology after adjusting for each of the other covariates (adjusted P values).
RESULTS
Surface expression of B7-1 by AdB7-infected tumor cells All tumors were tested for B7-1 glycoprotein expression by flow cytometry after infection with the AdB7 virus. Figure 1 represents an example of flow cytometric data from one tumor specimen after mock-infection with PBS, infection with AdB7, and infection with Addl70.3. The results of analyses from a number a different tumors are summarized in Table 1 . The spectrum of tumor pathologies included primary and metastatic sarcomas, adenocarcinomas, multiple myelomas, malignant melanomas, renal cell carcinomas, and squamous cell carcinomas. Tumor cells not infected with AdB7 never expressed B7-1. Infected tumor cells expressed B7-1 within 24 hours of infection; B7-1 expression persisted for Ն7 days and for Յ9 weeks in culture, likely because (Table 2) . Thus, on average, approximately onethird of tumor cells did not express MHC class I, in agreement with previous reports. 58 -69 There was significant heterogeneity in MHC class I expression among various tumors within each histology (particularly in malignant melanomas, in which the number of cells expressing MHC class I ranged from 11% to 94%), as well as among cells within each tumor specimen (Fig 2) . MHC class I expression by tumor cells did not change after infection with either AdB7 or Addl70.3, both of which are E1/E3-deficient adenovirus vectors: all tumor samples listed in Table 2 were tested, and all displayed the same pattern (Fig 3) .
CD28 expression by adult human NK cells
It is well established that murine NK cells express CD28, 29 but it has been reported that adult human NK cells are CD28
Ϫ . 31 Figure 4 shows the flow cytometry analysis of CD28 expression on CD56
ϩ PBLs (NK cells) from a normal donor. In this individual, 9.1% of PBLs were CD56 ϩ , and 42.1% of these cells were CD28 ϩ . NK cell-mediated cytotoxicity of autologous tumor cells Figure 5 shows the results of an NK cell-mediated cytotoxicity experiment that was carried out with tumor cells from a patient with colorectal adenocarcinoma. Flow cytometric analysis showed that 28% of the tumor cells expressed MHC class I Ag; 72% of the TMB7 cell population expressed B7-1. Of the PBLs of the patient, 42% expressed CD28. Figure 5 shows that, despite the low level of MHC class I expression, none of the *PBLs from five normal donors were incubated at 37°C for 18 hours in the presence of either IL-2 at 100 U/mL, IL-12 at 100 U/mL, or AIM-V medium alone at a concentration of 5 ϫ 10 6 cells/mL. These cells were subsequently harvested and stained with Abs against CD56, CD16, and CD28 for flow cytometric analysis. Results represent means Ϯ SD (n ϭ 5).
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ϩ HUMAN CANCER CELLS nontransduced TM cells were killed by autologous NK cells. However, 35% of the TMB7 cells were killed by autologous NK cells at an E:T ratio of 62:1. PBLs cultured in the presence of IL-2 for 45 hours prior to the 51 Cr release cytotoxicity assay killed 48% of TM cells and 97% of TMB7 cells at a 56:1 E:T ratio. Similar results were seen using PBLs cultured in the presence of IL-12: 22% of TM cells and 81% of TMB7 cells were killed by IL-12 LAK cells at an E:T ratio of 65:1. Figure 6 summarizes the results for all 24 patients. Unstimulated NK cells killed autologous B7-1 ϩ tumor cells to a greater degree than B7-1 Ϫ tumor cells, but this difference was not statistically significant (P ϭ .15, n ϭ 24). NK cells pretreated with IL-12 (100 U/mL) showed a statistically significant increase in the killing of B7-1 ϩ tumor cells (P ϭ .05, n ϭ 19). NK cells pretreated with IL-2 (100 U/mL) had an increased ability to kill all tumor cells, whether B7-1 ϩ or not. All effector cells (unstimulated NK cells as well as LAK cells) killed K562 control cells very efficiently, suggesting that these were NK cells and not CTLs. Furthermore, none of the PBLs were stimulated by tumor cells in vitro before the chromium release assay. We also showed that high MHC class I expression correlated with decreased LAK-mediated cytotoxic activity (P Ͻ .05), again arguing in favor of these effector cells being NK cells. These results suggest that B7-1 expression can play a significant role in NK cell-mediated killing of human cancer cells.
Regression analysis showed that, after adjusting for tumor pathology and the degree of MHC class I expression, the degree of B7-1 expression on tumor cells within the TMB7 group was significant and positively correlated with NK cell-mediated cytotoxicity, regardless of whether the NK cells had been pretreated with cytokines (P ϭ .01, .05, and .01, respectively, for unstimulated NK cells, NK cells pretreated with IL-2, and NK cells pretreated with IL-12). High levels of tumor MHC class I expression correlated with decreased NK cell-mediated cytotoxic activity, and this correlation was statistically significant when the NK cells were pretreated with cytokines (P ϭ .04 and .03 for IL-2-treated and IL-12-treated NK cells, respectively). Tumor pathology did not affect NK cell-mediated cytotoxic activity against freshly resected autologous cancer cells.
T-cell-proliferative responses to autologous tumor cells T-cell proliferation assays were carried out with tumor cells and PBLs from 66 patients. PBLs from seven patients failed to respond to PHA (PI Ͻ 2.5), presumably due to generalized immunosuppression from the malignant disease process or its treatment, and these results were not included in subsequent analyses. PBLs from one patient displayed a minor response to PHA (PI ϭ 4.1) but failed to respond to 100 U/mL IL-2 (PI ϭ 1.9); results from this patient were also excluded from further analysis. Of the remaining 59 patients, proliferation assays were carried out with either 100,000 tumor cells/well (36 patients) or 5000 tumor cells/well (29 patients). Lymphocyte responses in those patients in which proliferation assays were performed using both tumor cell concentrations (n ϭ 9) were not statistically different.
In the first group of studies (using 100,000 tumor cells/well), we found that B7-1 ϩ tumor cells induced an enhanced lymphocyte-proliferative response in 6 of 36 patients (17%); however, the proliferative responses to the TM, TMB7, and TMAd groups were all weak (PI Ͻ 1), and there was no statistical difference in the mean responses to the three tumor groups (adjusted P ϭ .67). The number of tumor cells obtained from 12 of the patients was sufficient to allow for experiments in which PBLs and tumor cells were cocultured in the presence of cytokines (IL-2 and/or IL-12). There was no statistical difference in the lymphocyte-proliferative responses to the TM, TMB7, and TMAd groups, but an increased degree of B7-1 expression in the TMB7 group was directly correlated with an increased proliferative response in the groups cultured in the presence of lowdose IL-2 (5 U/mL), IL-12 (100 U/mL), or a combination of the two (P ϭ .003, .04, and .002, respectively, after adjusting for pathology and the degree of MHC expression).
In the second group of studies (using 5000 tumor cells/well), there was an increased lymphocyte PI in response to TMB7 tumor cells in 12 of 27 patients (44%). Again, the mean PIs for lymphocytes cultured with the three tumor groups (in the absence of exogenous cytokines) were not statistically different (Fig 7; adjusted P ϭ .09). The mean proliferative responses correlated with degree of MHC class I expression (adjusted P ϭ .03). Figure 7 shows that, with the addition of high-dose IL-2 (100 U/mL), there was an increase in the lymphocyte PI for all tumor groups, with no significant difference between the three groups (adjusted P ϭ .12). However, with the addition of low-dose IL-2 (5 U/mL), there was a statistically significant difference in the lymphocyte response between the three groups (adjusted P ϭ .001). A similar difference was noted in responses when lymphocytes were tested in the presence of IL-12 (100 U/mL) (adjusted P ϭ .015). When both IL-2 (5 U/mL) and IL-12 (100 U/mL) were present in the culture medium, there was an increase in lymphocyte proliferation in all three groups, with no statistically significant difference between them (adjusted P ϭ .23). These data suggest that the requirement for B7-1-mediated costimulation of T-cell proliferation can be circumvented by a high concentration of IL-2 or a combination of IL-12 and a low concentration of IL-2. Differences in T-cell responses to B7-1-expressing tumor cells are seen only in situations in which there is inadequate cytokine costimulation.
Our data also show that the proliferative response elicited by TMB7 cells in the presence of both cytokines was blocked by a murine Ab (BB1) that recognizes human B7-1 (P ϭ .02) but not by isotype control mIgG1 Ab (Fig 7) . Interestingly, BB1 also caused a reduction in the proliferative response elicited by B7-1 Ϫ tumor cells. It is possible that, among the PBLs and tumor-infiltrating lymphocytes within the experimental wells, there were professional APCs (dendritic cells, B cells, and macrophages) that expressed B7-1 and presented tumorspecific (as well as non-tumor-specific) Ag that elicited a minor response in the TM and TMAd groups, and that this response was blocked by BB1.
DISCUSSION
In this report, we demonstrate that B7-1 expression on the surface of human cancer cells can play a significant role in autologous lymphocyte responses when combined with the use of cytokines. Other studies have shown that IL-12, even in association with IL-2, has no significant ability to induce proliferation in fresh resting PBLs. 41, 42 However, IL-12 can enhance the T-cell proliferation of 5-to 6-day-old cultures induced by a variety of stimuli (mitogenic lectins, allogeneic cells, anti-CD3 Abs, and phorbol diesters). In conjunction with IL-2, IL-12 can act in an additive, synergistic, or antagonistic fashion depending upon the dose and timing of its use. 41, 42, 70 High-dose IL-2 (100 U/mL) has been reported to induce the proliferation of T cells even in the absence of antigenic stimulation. 71 IL-2 at suboptimal concentrations (5 U/mL), however, does not mediate CTL proliferation. IL-12 (50 -100 U/mL) can cause the proliferation of IL-2-activated peripheral blood mononuclear cells that have received suboptimal concentrations of IL-2 (3-10 U/mL), but only if the cells have been recently costimulated with Ag or solid-phase ␣CD3 Ab. 41 Therefore, we had expected to improve both the sensitivity and specificity of detecting antitumor lymphocyte responses by combining these two cytokines in vitro. Figure 7 shows that there was an increase in lymphocyte proliferation in response to autologous tumor cells when cocultured in the presence of IL-2 (5 U/mL) and IL-12 (100 U/mL) compared with either cytokine alone, but this response was modest in comparison with the response elicited in the presence of high-dose IL-2 (100 U/mL). Furthermore, the increased cytokine costimulation obviates the dependence upon B7-1 costimulation, because significant B7-1-mediated increases in lymphocyte proliferation were noted only in those groups with suboptimal stimulation with low-dose IL-2 (5 U/mL) or IL-12 (100 U/mL). These results, along with the lack of response noted in the absence of cytokines, suggest that T-cell activation is determined by a predetermined activation threshold, 72 and that costimulation, either by membrane-bound B7-1 or by soluble cytokines such as IL-2 or IL-12, renders T cells more sensitive to antigenic stimulation.
Our most interesting results are those that show that NK cell-mediated killing of B7-1 ϩ tumor cells was greater than that of B7-1 Ϫ tumor cells, and that this difference is most significant when PBLs are pretreated with IL-12 (100 U/mL). Although we did not purify the NK cell population, it is highly unlikely that the observed effects are mediated by CTLs. Whether this effect is mediated by B7-1 interaction with the CD28 receptor (which we show is expressed by approximately one-third of human NK cells) or with another, yet unidentified, receptor remains to be determined. Chambers et al have recently shown that the triggering of mouse NK cells by B7-1 occurred even in the absence of CD28 and could not be blocked by either anti-CD28 or anti-CTLA-4 Abs, suggesting that the B7-1-mediated cytotoxic activity of NK cells may be due, at least in part, to receptors other than CD28. 28 It has been proposed that the final outcome of NK cell-mediated cytotoxicity is a result of the interaction between triggering and inhibitory ligands and receptors, and that the net result of these interactions determines susceptibility to lysis. 28, 73 We show that B7-1 molecules help trigger NK cell cytotoxicity, particularly when PBLs have been pretreated with IL-12; however, further studies are needed to identify the receptors and signaling pathways involved. Our data also provide further support for the hypothesis that MHC class I molecules act as inhibitory signals for NK cell-mediated cytotoxic activity. 74 Many of our T-cell PIs were negligible (mean PIs of Ͻ5). In addition to the experimental conditions that are used to stimulate CTLs in vitro, the ability to detect lymphocyte responses also depends upon the antitumor CTL precursor frequency. The number of T-cell precursors specific for any particular tumor Ag in unprimed hosts has been shown to be extremely low. [75] [76] [77] Vose reported frequencies of CTLs against lung and breast tumors ranging from 1/1500 to 1/4700 PBLs. 75 More recently, Boon and colleagues reported that the frequency of antitumor CTL precursor cells of seven melanoma patients ranged from 1/900 to 1/33,000 PBLs. 76 Improved stimulation methods in their protocols, involving repeated stimulation with irradiated autologous tumor cells in the presence of IL-2 and IL-4 for a period of 2-4 weeks, may have led to an increased frequency of precursors. Our results are in keeping with these reports and reflect the nature of human tumor immunogenicity in cancer patients.
Our results suggest that the successful immunotherapy of cancer patients could potentially be mediated by genetically modifying tumor cells to express B7-1 and secrete IL-12. We have shown that the AdB7 vector is a rapid and efficient means of gene delivery, particularly in dissociated cells from solid tumors. Because lymphocyte responses are greater when cells express higher degrees of B7-1, patients with solid tumors are likely better candidates for AdB7-mediated gene therapy than patients with multiple myeloma, and patients with adenocarcinomas may not benefit to the same degree as patients with other forms of solid tumors (sarcomas, renal cell carcinomas, and malignant melanomas). To date, our AdB7 vector has only been used to transduce tumor cells in vitro, but the vector could also be used to infect tumors directly, in vivo. We (F.L.G.) have used other Ad vectors (Ad-IL-4, Ad-IL-2, and Ad-IL-12) in mouse tumor models and have shown efficient cytokine gene transfer after direct injection in vivo, with corresponding functional immune responses. 78 -81 Cusack et al have also demonstrated high levels of gene transduc-tion in human lung tumors after an intralesional injection of recombinant adenovirus. 82 In the clinical setting, malignant lesions could be treated with percutaneous intratumoral AdB7 injections; these lesions could also be resected, infected ex vivo, irradiated, and inoculated into the patients as tumor vaccines. Patients whose tumors are inoperable because of tumor location rather than tumor size might be expected to have better responses, because low tumor burden has been shown to be important for success in animal models. Ad vectors expressing B7-1 and IL-12 have recently been generated (Pützer BM, unpublished observations; Hitt M, Muller WJ, Emtage P, Gauldie J, Graham FL, unpublished observations) and will soon be available for further in vitro work and clinical studies in the adjuvant and palliative setting. Plans for clinical trials testing the utility of B7-1-mediated gene therapy in cancer patients are underway. We thank the surgeons at Mount Sinai Hospital for providing us with tumor resection specimens and their patients for giving us permission to obtain blood for our studies. We also acknowledge the assistance Dr. Keith Stewart of the Toronto Hospital for providing samples from patients with multiple myeloma. We thank our statistical consultants, Dr. M.J. Evans, P. Austin, and B. Kowalski, for their assistance, Drs. John Roder and Robert Rottapel for useful discussions, and Cheryl Smith for her expert advice on flow cytometry. Henry Yu deserves mention for his help in the lab.
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